Search Results for 'Xience Bvs'

Everolimus-eluting Bioresorbable Vascular Scaffolds in Pati

• debby-jeon
• 35 Slides

The ABSORB III trial. Dean J. Kereiakes, MD, . St...

A Randomized

• tatyana-admore
• 25 Slides

Comparison of . Everolimus-­. Eluting . Absorb B...

ABSORB China

• mitsue-stanley
• 20 Slides

: . Two-Year Clinical . Results in Patients with ...

"Impact of Procedural Technique on long term adverse outcom

• conchita-marotz
• 36 Slides

trials“. Manish Narang. Sr. Medical Advisor-APJ...

The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb

• conchita-marotz
• 0 Slides

Everolimus. Eluting . Bioresorbable. Vascular S...

The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb

• briana-ranney
• 0 Slides

Everolimus. Eluting . Bioresorbable. Vascular S...

ABSORB China : Two-Year Clinical

• bitechmu
• 20 Slides

Results in Patients with Coronary Artery Disease R...

Outcomes of Absorb Bioresorbable Scaffolds with Improved Technique in an Expanded Patient Populatio

• limelighthyundai
• 43 Slides

Gregg W. Stone MD. Stephen G. Ellis MD and Dean J....

• haroublo
• 21 Slides

Saturday. , Sep . 22. , 2018, 12:40 PM – 12:52 P...

A Randomized Comparison of

• melanie
• 24 Slides

Everolimus-­. Eluting . Absorb Bioresorbable Vasc...

ABSORB II Acute gain for BVS vs. DES: 1.15

• anderson
• 1 Slides

vs. 1.46 mm, . p < 0.0001; . IVUS showed lower ...

jx009crrx008cnx009b M mx009cx009bx009crx008c zx

• eve
• 64 Slides

1.ln‹Œaor RŒšo...